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Key Points:  
• In a nationally-representative sample, over 40% of patients with dementia were 
prescribed a psychotropic medication. 
• The burden of neuropsychiatric symptoms is highest among those on antipsychotics and 
sedative-hypnotics. 
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• Controlling for level of neuropsychiatric symptoms, caregiver distress, and dementia 
stage, nursing home residence was the characteristic most strongly associated with 
psychotropic use. 
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ABSTRACT 
Objective: To determine the national prevalence of psychotropic use and association with 
neuropsychiatric symptoms among patients with dementia.  
Methods: Participants diagnosed with dementia (n=414) in the Aging, Demographics, and 
Memory Study, a nationally-representative survey of US adults >70 years old. Diagnosis was 
based on in-person clinical assessment and informant interview. Information collected included 
demographics, place of residence, 10-item Neuropsychiatric Inventory (NPI), and prescribed 
medications (antipsychotic, sedative-hypnotic, antidepressant, mood stabilizer). 
Results: Of 414 participants with dementia, 41.4% were prescribed a psychotropic medication, 
including 84.0% of nursing home residents and 28.6% of community-dwellers. 23.5% were 
prescribed an antidepressant. Compared to the total NPI score of those on no medication (4.5), 
those on antipsychotics and those on sedative-hypnotics had much higher scores (respectively: 
12.6, p<0.001; 11.8, p=0.03), though those antidepressants did not (6.86, p=0.15). A larger 
proportion of patients on antipsychotics exhibited psychosis and agitation compared with those 
on no medication, while those on antidepressants exhibited more depressive symptoms. In 
multivariable logistic regression that included dementia severity and nursing home residence, 
nursing home residence was the characteristic most strongly associated with psychotropic use 
(odds ratio ranging from 8.96 [p<0.001] for antipsychotics to 15.59 [p<0.001] for sedative-
hypnotics). More intense psychotic symptoms and agitation were associated with antipsychotic 
use; more intense anxiety and agitation were associated with sedative-hypnotic use. More 
intense depression and apathy were not associated with antidepressant use. 
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Conclusions: In this nationally-representative sample, 41.4% of patients were taking 
psychotropic medication. While associated with NPS, nursing home residence was most 
strongly tied to use. 
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INTRODUCTION 
 Dementia affects a large and growing number of older adults (Plassman et al., 2007). 
Although cognitive impairment is the clinical hallmark of dementia, neuropsychiatric symptoms 
(NPS) are exceedingly common and often dominate disease presentation (Kales et al., 2015). 
NPS occur in dementia of all types in clusters or syndromes such as depression, psychosis, 
agitation, and apathy (Lyketsos et al., 2011). Thirty percent of the cost of caring for community-
dwelling patients with dementia is directly attributable to NPS management (Schnaider Beeri et 
al., 2002), while just 1 or 2 NPS symptoms are associated with an additional 10 hours weekly (a 
doubling) of active help from caregivers (Okura and Langa, 2011). Such symptoms, as opposed 
to core cognitive symptoms, often create the most difficulties for patients, caregivers, and 
providers, and lead to earlier nursing home placement (Yaffe et al., 2002). Psychotropic use in 
patients with dementia is an area of intense interest, given the distressing nature of NPS 
thought to trigger medication use, limited evidence of benefit from medications, and ever-
growing evidence of harms associated with use, both for older adults in general (American 
Geriatrics Society, 2015, Beers, 1997) and patients with dementia in particular (Schneider et al., 
2005, Maust et al., 2015). While prescribing in the nursing home has been an area of significant 
attention, a recent report from the Government Accountability Office noted that less is known 
about antipsychotic prescribing in the community (US Government Accountability Office, 2015). 
Studies of psychotropic use in patients with dementia often come from large 
administrative or claims data such as Medicare or the Veterans Affairs system (Kales et al., 
2011, Huybrechts et al., 2011) and have two key limitations. First, the use of psychotropic 
medications in patients with dementia in these observational analyses is generally presumed to 
be for treating NPS, though this assumption has not been specifically tested. NPS are generally 
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not billed for nor documented as part of routine clinical care in a manner that is easily accessible 
for research purposes. In addition, the sensitivity and specificity of a dementia diagnosis in 
observational data are limited and may lead to mis-classification and bias, as mild dementia 
cases may be excluded or delirium cases may be inappropriately classified as having dementia 
(Taylor et al., 2009). One previous study in a representative US sample of patients with 
clinically-diagnosed dementia examined the association between NPS and antipsychotic use 
and, surprisingly, did not find a significant association (Rhee et al., 2011). 
 This analysis uses the Aging, Demographics, and Memory Study (ADAMS) (Langa et al., 
2005), a sub-study of the Health and Retirement Study (HRS). ADAMS is a survey of all US 
adults over the age of 70 designed to derive nationally-representative estimates of both 
prevalent and incident dementia. We first estimate the prevalence of antipsychotic, sedative-
hypnotic, antidepressant, and mood stabilizer use among adults with dementia and describe the 
clinical characteristics associated with use, focusing on NPS. In light of limited evidence that 
psychotropic medications effectively treat NPS (Kales et al., 2015), we hypothesized that 
prescribing would be associated with higher overall NPS prevalence. In addition, we 
hypothesized the following symptom-medication associations: delusions, hallucinations, and 
agitation with antipsychotics; anxiety and agitation with sedative-hypnotics; and depression and 
apathy with antidepressants. We included the NPS domain of apathy in the antidepressant 
analysis as there is a significant overlap in symptoms between depression and apathy, while 
caregivers and even providers may not distinguish the two (Landes et al., 2001). 
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METHODS 
Sample 
The ADAMS (Langa et al., 2005) sample was drawn from the larger Health and 
Retirement Study (HRS), an ongoing, nationally-representative sample of individuals >50 years 
that began in 1992 (Sonnega et al., 2014). ADAMS was designed to provide nationally 
representative data on the antecedents, prevalence, outcomes, and costs of dementia and 
began with a stratified random subsample of 1,770 individuals selected from HRS respondents 
>70 years of age who completed the 2000 or 2002 HRS wave. Of those HRS respondents 
selected for participation, 856 (56% of eligible, living participants) consented to the ADAMS 
baseline assessment (Wave A) that was conducted from 2001 to 2003.  
 Participants completed a 3- to 4-hour assessment by a nurse and neuropsychology 
technician in their residence. As summarized by Plassman et al. (Plassman et al., 2011), a 
knowledgeable informant (usually a spouse or adult child) was identified to provide the 
following: (1) detailed history and current assessment of cognition and function; (2) medical 
history; (3) current medications; and (4) current NPS. The informant was a spouse or a child in 
73% of cases and lived with the participant in 53% of cases (Okura et al., 2010). Each 
participant completed neuropsychological measures and a neurological examination. The same 
assessment was performed for all participants and informants, including nursing home 
residents. The ADAMS multi-specialty consensus panel reviewed all information from the in-
person evaluation and relevant medical records. The dementia diagnosis was made using 
criteria from the Diagnostic and Statistical Manual of Mental Disorders (DSM)-III-R and DSM-IV.  
 As part of the purpose of ADAMS was to understand incident dementia, 3 follow-up 
waves (Waves B-D) were completed at two-year intervals, with the same information collected 
This article is protected by copyright. All rights reserved.
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as for Wave A. Final assessments (Wave D) began in 2008. Participants selected for follow-up 
were generally patients who had not yet been diagnosed with dementia; participants diagnosed 
with dementia did not undergo follow-up. The sample for the present analysis includes all 414 
participants (of 856 consenting participants at baseline) that received a final diagnosis of 
dementia during either the baseline assessment (n=308) or follow-up (n=40, 47, and 19 for 
waves B, C, and D, respectively). The data used for analysis is from the Wave at which the 
participant was diagnosed with dementia.  
 The institutional review boards at the University of Michigan and Duke University 
Medical Center approved all study procedures; study participants or surrogates provided 
informed consent. ADAMS data are available online (http://hrsonline.isr.umich.edu/index.php). 
 
Measurements 
Dementia Assessment and Diagnosis 
 The consensus panel determined the presence of dementia, which was subtyped into: 
Alzheimer’s dementia (McKhann et al., 1984), vascular dementia (Román et al., 1993), or other. 
Dementia severity was classified using the Clinical Dementia Rating Scale (CDR) (Morris, 
1993). As in prior studies, mild dementia was defined as a CDR stage of 0.5-1.0, moderate as 
CDR 2.0, and severe as CDR 3.0-5.0 (Okura et al., 2010, Lyketsos et al., 2000). Testing 
included the Mini-Mental State Examination (MMSE) (Folstein et al., 1975); please refer to 
Langa et al. (Langa et al., 2005) for the full neuropsychological battery. 
 
Sociodemographic Characteristics 
This article is protected by copyright. All rights reserved.
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 The analysis includes participant age, sex, ethnicity, education, and nursing home 
residence.  
 
Medical History 
 Informants were asked if the participant had history of the following: stroke, fall, seizure 
disorder, hypertension, heart attack, diabetes, chronic respiratory problems, cancer, alcohol 
use, tobacco use, bipolar disorder, or schizophrenia. In addition, the informants were asked 
whether, in the participant’s lifetime, they had experienced a >2 week period of depressed mood 
or anhedonia, along with follow-up questions to determine if the participant met DSM-IV criteria 
for a lifetime history of a major depressive episode. Informants were also asked if the participant 
had ever seen a psychiatrist for a “memory problem” or for “concerns with his/her memory or 
thinking.” 
 
Medications 
 Participants (or the designated informant) were mailed a medication form prior to the 
ADAMS visit and asked to have information available at the time of assessment for medications 
used in the previous two weeks; the study nurse examined medication containers for 
confirmation. We determined the total number of medications used and classified psychotropics 
as follows: antipsychotic, sedative-hypnotic, antidepressant, and mood stabilizer (please see 
eTable 1 for medications and specific exclusions). We also determined whether they were on a 
cholinesterase inhibitor or memantine. 
 
Neuropsychiatric Symptoms 
This article is protected by copyright. All rights reserved.
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 NPS were assessed using the 10-item Neuropsychiatric Inventory (NPI) (Cummings, 
1997). Informants were asked whether, in the past month, the participant exhibited symptoms 
from 10 domains: delusions, hallucinations, agitation/aggression, depression, apathy, elation, 
anxiety, disinhibition, irritability, and aberrant motor behaviors. If informants answered “yes” to 
the domain-specific screening item, they were asked follow-up questions to confirm presence of 
the symptom. If confirmed, participants were asked to rate frequency on a 4-point scale and 
severity on a 3-point scale. Each NPI domain then received a score equal to frequency x 
severity, yielding a domain range of 0-12 and a total NPI score of 0-120. After describing each 
NPI domain, the informant was asked, “How emotionally distressing do you find this behavior?” 
on a scale from 0 to 5, yielding a NPI caregiver distress score of 0-50. 
 
Analyses 
 Population sample weights were constructed to account for probability of selection in the 
stratified longitudinal sample design and to adjust for differential participation and non-response 
in ADAMS for each assessment wave (Heeringa et al., 2009). Using the longitudinal weight 
allows the ADAMS sample to be nationally representative of older adults >70 years old with 
dementia from 2002-2008.  
We estimated the proportion of participants with dementia on psychotropic medication 
and the number of persons this represents nationally. We compared demographic and clinical 
characteristics of each medication group with the non-user group using an adjusted Wald test. 
For participants prescribed medication from several groups, we used an antipsychotic > 
sedative-hypnotic > antidepressant hierarchy to assign the participant to one mutually exclusive 
group (e.g., a respondent prescribed risperidone and lorazepam was assigned to the 
This article is protected by copyright. All rights reserved.
 11 
antipsychotic group). Mood stabilizers were included in the antipsychotic group for analysis 
given: 1) the small number of participants that reported mood stabilizers (n=13); 2) evidence 
that mood stabilizers have been used as an alternative to antipsychotics in patients with 
dementia (Kales et al., 2011); and 3) the mortality risk associated with mood stabilizers is similar 
to antipsychotics (Kales et al., 2012). 
 We then created logistic regression models to examine the association of NPS with 
psychotropic medication use. First, for each medication group, we used the NPS burden 
(symptoms present on 0, 1-2, >3 NPI domains, following Okura et al. (Okura and Langa, 2011, 
Okura et al., 2010)) as the primary predictor in a logistic regression predicting the odds of 
medication use. Initial models adjusted for age, gender, and survey year to account for secular 
trends in the use of medication; final models included nursing home residence and dementia 
stage. Finally, we created logistic regression models to explore the association between specific 
hypothesized NPS clusters and medication use, adjusting for caregiver distress. Analyses were 
performed in Stata 13.1 (StataCorp LP, College Station, TX) using two-sided tests of statistical 
significance, with a P value <0.05 considered statistically significant.  
We performed a variety of sensitivity analyses. First, we ran the final regression models 
limiting the NPS domain prevalence categories to clinically significant symptoms (NPI domain 
score >4) as opposed to simply prevalent NPS. In addition, we tested the models using non-
exclusive medication groups. Finally, we tested the adjusted regression models with the 
following alternative medication groups: 1) antipsychotics excluding mood stabilizers; 2) 
benzodiazepines excluding other sedative-hypnotics; and 3) antidepressants limited to only 
selective serotonin and serotonin-norepinephrine reuptake inhibitors. 
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RESULTS 
 In this nationally representative sample of patients with dementia, 41.4% (95% 
confidence interval [CI] 35.4-47.6%) were on at least one psychotropic medication, representing 
2.8 million people (CI 2.0-3.5 million). Overall, 23.1% (CI 16.6-31.2%) of these participants with 
dementia resided in a nursing home. Psychotropic users comprised 84.0% (CI 76.2-89.5%) of 
nursing home residents and 28.6% (CI 20.9-37.8%) of community-dwellers. Antidepressants 
were the most commonly prescribed medication (Table 1), followed by sedative-hypnotics, 
antipsychotics, and mood stabilizers. 14.7% (CI 10.2-20.8%) of participants were on 
benzodiazepines, which comprised the majority of sedative-hypnotic prescriptions.  
 Table 2 presents demographic and clinical characteristics of patients with dementia, 
classified by psychotropic group. The groups were similar across most demographic 
characteristics, though patients residing in nursing homes comprised a larger share of every 
psychotropic group than those on no psychotropic medication. The antipsychotic group had 
larger proportions of patients with both moderate and severe dementia than the no medication 
group, as well as an MMSE score that was 6 points lower (13.2 [CI 10.3-16.1] v. 19.2 [CI 17.7-
20.6]; F=12.27, p=0.0017). Informants reported that the vast majority of patients in all groups 
had never seen a psychiatrist to evaluate their memory or thinking.  
Participants in the antipsychotic and sedative-hypnotic groups had significantly higher 
total NPS. The estimated prevalence of NPI domains by medication group is shown in Figure 1 
(see eFigure 1 for average domain scores). Compared with those on no medication, a larger 
proportion of participants on antipsychotics exhibited delusions (40.6% [CI 16.2-64.9%] v. 7.4% 
[1.5-13.4%]; F=8.25, p=0.008), hallucinations (29.9% [CI 6.7-53.1%] v. 6.4% [0.3-12.5%]; 
F=4.25, p=0.05), and agitation (34.1% [CI 15.8-52.4%] v. 12.0% [CI 5.5-18.6%]; F=6.30, 
This article is protected by copyright. All rights reserved.
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p=0.02). The sedative-hypnotic group had a higher prevalence of delusions than those on no 
medication (31.8% [CI 6.4-57.2%] v. 7.4% [1.5-13.4%]; F=4.49, p=0.04). Depression was more 
prevalent among those on antidepressants than the no medication group (51.9% [CI 34.6-
69.3%] v. 18.7% [10.4-26.9%]; F=13.34, p=0.001).  
 Logistic regression models estimating the association between overall NPS burden (i.e., 
prevalent symptoms) and medication use are presented in Table 3. In initial models, the highest 
category of NPS burden (symptoms in >3 categories) was associated with significantly 
increased odds of medication use for all groups. In final models that included nursing home 
residence and dementia severity, the characteristic most strongly associated with increased 
odds of medication use was nursing home residence. When NPS burden was limited to clinically 
significant symptoms (eTable 2), the association between NPS burden and psychotropic use 
was attenuated for all groups but antipsychotics. When overlap was allowed between 
psychotropic groups (eTable 3), NPS burden at >3 domains was associated with use for all 3 
groups. Nursing home residence was still the characteristic most strongly associated with 
psychotropic use in these sensitivity analyses, as well as using the more narrowly-defined 
medication groups. 
 The association of specific NPS clusters with medication use is presented in Table 4. As 
hypothesized, additional symptom intensity of delusions, hallucinations, or agitation was 
associated with antipsychotic use, while additional anxiety or agitation was associated with 
sedative-hypnotic use. However, more intense depression and apathy were not associated with 
antidepressant use. Caregiver distress was not significantly associated with any class of 
psychotropic use. Again, nursing home residence was the characteristic most consistently 
associated with use across psychotropic groups. Using overlapping medication groups had 
This article is protected by copyright. All rights reserved.
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limited effect on the general magnitude and statistical significance of findings (eTable 4), as was 
also the case with sensitivity analyses using more narrow medication groups. 
This article is protected by copyright. All rights reserved.
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DISCUSSION 
 In this nationally representative sample, over 40% of patients diagnosed with dementia 
based on an in-depth clinical assessment were taking a psychotropic medication, including 84% 
of nursing home residents with dementia and 29% of those in the community. Both the overall 
and community-based rates are far higher than the rate of 11.1% among the US adult 
population described by Paulose-Ram et al. (Paulose‐Ram et al., 2007) using data from the 
National Health and Nutrition Examination Survey (NHANES) at a comparable time, though 
NHANES does not include nursing home patients. They found prevalence of individual 
medication classes as follows: antidepressant (8.1%), sedative-hypnotic (3.5-3.8%), 
antipsychotics (0.8-1.0%), and mood stabilizers (0.3-0.4%). In contrast, we found the following 
prevalence among participants with dementia: antidepressants (23.5%), sedative-hypnotic 
(18.2%), antipsychotic (11.1%), and mood stabilizers (1.5%). Even excluding nursing home 
medication users from each group, these remain high rates of psychotropic medication use for 
any group, especially adults with an average age over 80. The rate of cholinesterase inhibitor 
and memantine use found is consistent with analyses from the Medicare Current Beneficiary 
Survey from a similar time period (Gruber-Baldini et al., 2007). 
This high rate of psychotropic utilization is most likely an attempt to address dementia-
associated NPS, despite limited evidence of benefit (Kales et al., 2015). The prevalence of NPI 
domains and the average NPI score among the ADAMS participants with dementia were similar 
to other population-based studies (Lyketsos et al., 2000, Lyketsos et al., 2002) though the NPI 
total among medication users was relatively low compared to medication trials (Banerjee et al., 
2011, Schneider et al., 2006). Our analysis, however, is the first to confirm the assumption that 
This article is protected by copyright. All rights reserved.
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psychotropic use is associated with patient NPS burden. As hypothesized, more intense 
symptoms of psychosis and agitation were associated with antipsychotic use, while more 
intense anxiety and agitation were associated with sedative-hypnotic use. Use of 
antidepressants was associated with higher prevalence of NPS domains but not, however, with 
more intense depression or apathy. It may be that antidepressants effectively treat these 
symptoms, but the high prevalence of depressive symptoms among ADAMS participants as well 
as clinical trial evidence would suggest otherwise (Rosenberg et al., 2010, Banerjee et al., 
2011). Alternatively, as the most commonly used medication for this population, antidepressants 
are possibly being used broadly and non-specifically to treat NPS. Finally, some evidence 
suggests that antidepressants are prescribed in the absence of any significant mental diagnosis 
or symptoms altogether, which may be true for these ADAMS participants, as well (Takayanagi 
et al., 2015, Maust et al., 2011). This is particularly concerning, as antidepressants were the 
most commonly prescribed class of medication, used in nearly one quarter of the sample. The 
strong association between residing in a nursing home and psychotropic use of all types 
suggests that efforts to minimize antipsychotic prescribing in nursing homes are critical. It will be 
important to study whether this has simply led to a compensatory increase in other psychotropic 
use. To our surprise, additional caregiver distress was not associated with psychotropic use in 
our models. 
To our knowledge, the only prior analysis to examine the association of NPS and 
psychotropic use (antipsychotics specifically) in a nationally-representative clinical sample used 
baseline Wave A ADAMS data (Rhee et al., 2011) and, surprisingly, the authors did not find an 
association between neuropsychiatric symptoms and antipsychotic use. However, we believe 
there are two key distinctions that account for this discrepancy. First, their logistic regression 
This article is protected by copyright. All rights reserved.
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compared antipsychotic users to non-antipsychotic users, whereas our analyses compared 
antipsychotic users to those with no psychotropic medication use. Given our findings of the 
relatively high prevalence (count of NPI domains) and burden (NPI total) of NPS among the 
sedative-hypnotic users, it follows that the association between NPS and antipsychotic use 
would be attenuated/absent when sedative-hypnotic users were included in the comparison 
group. Second, they used the NPI in an unconventional manner by counting domains and then 
using this as a continuous measure (range: 0-10). As such, they report a “Neuropsychiatric 
Inventory, mean” among antipsychotic users of just 2.16 (this is the reported NPI total, not a 
single domain score) and 1.35 among non-antipsychotic users. This NPI measure is then used 
as a continuous variable in the logistic regression. It is not surprising, then, that their regression 
model would find no association between a 1-unit change in NPI on this continuous scale and 
antipsychotic use, as the groups differed by just 0.81 units (i.e., 2.16 minus 1.35). Ultimately, we 
attempted to construct variables and models in a manner that most accurately captures and 
then tests the hypothesized associations between NPS and prescribing in clinical practice.  
The key limitation of this work is its cross-sectional nature: we cannot address change in 
medication use and corresponding change in NPS burden, nor do we know the prescribers’ 
rationale for prescribing or plans to adjust. In addition, some of the psychotropic use may reflect 
treatment for a long-standing mental illness rather than the more recent development of NPS 
(e.g., antidepressants for Major Depressive Disorder prior to development of dementia). Another 
limitation is that several years have passed since ADAMS was completed, and there has 
possibly been a shift in psychotropic use since that time. Those patients with prevalent 
dementia were drawn from the baseline survey, while the subsequent (incident) cases added to 
the sample were less likely to have advanced disease. However, it is unlikely that the overall 
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prevalence of psychotropic use has declined much—Kales et al.’s analysis of antipsychotic 
trends using national VA administrative data found a relatively constant rate of overall 
psychotropic use (Kales et al., 2011). There may have been shifts in the type of psychotropic 
used, as they found a small shift away from antipsychotics following the 2005 FDA black-box 
warning (US Food and Drug Administration, 2005) and an increase in use of other psychotropic 
agents, including anticonvulsants. Antipsychotic use among dementia patients in nursing homes 
has declined somewhat recently, likely in response to a concerted two-year effort initiated by the 
Centers for Medicare and Medicaid Services associated with a 15.1% reduction (US 
Government Accountability Office, 2015). However, it is unknown if community prescribing of 
antipsychotics to patients with dementia in the US has changed; use overall among adults has 
actually increased (Olfson et al., 2012). As noted above, it is likely that any decrease in 
antipsychotics would have been accompanied by a compensatory increase in the use of other 
psychotropic medication as clinicians shift to alternative strategies to manage NPS 
(Porsteinsson et al., 2014). While evidence regarding the risks associated with psychotropic 
prescribing in dementia has grown since the ADAMS study period, there have been few 
advances in the structure of care delivery or payment that would have encouraged more robust 
delivery of behavioral interventions and substantially reduced psychotropic treatment. Finally, 
the ADAMS participation rate was 56%, though this is comparable to other population studies of 
older age groups (Tell et al., 1993, Rockwood et al., 2004). Sampling weights were derived to 
account for non-response bias, and U.S. population estimates for older adults derived from 
ADAMS closely match the U.S. Census Bureau (Plassman et al., 2008). 
Each class of psychotropic medication studied is associated with a range of risks for 
older adults (American Geriatrics Society, 2015), from nausea or hyponatremia with a selective 
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serotonin reuptake inhibitor (SSRI) (Banerjee et al., 2011) to more serious consequences such 
as falls with benzodiazepines (Wang et al., 2001) and mortality with antipsychotics (Schneider 
et al., 2005). Potential harms associated with antipsychotic alternatives should not be 
minimized, as even SSRI-related nausea could be distressing to a patient with cognitive 
impairment and potentially exacerbate NPS, leading to the perceived need for more medication. 
While NPS are distressing, caregivers, providers, and facilities caring for these patients need to 
realistically consider whether there is sufficient evidence of benefit to justify this high rate of 
psychotropic use.   
 
  
This article is protected by copyright. All rights reserved.
 20 
ACKNOWLEDGMENTS 
The authors would like to acknowledge Ryan McCammon for his input regarding use and 
analysis of ADAMS data. 
 
This article is protected by copyright. All rights reserved.
21 
Table 1. National Prevalence Estimates of Psychotropic Medicationa Use in Patients with Dementia from the Aging, 
Demographics, and Memory Study (n=414) 
  None Antipsychotic Sedative-Hypnotic Antidepressant Mood Stabilizer 
Participants, n  
 
234 
 
56 
 
70 
 
103 
 
13 
 
Overall weighted 
percent (95% CI) 
58.6  
(52.4-64.6) 
10.9  
(7.6-15.3) 
19.5  
(14.2-26.2) 
23.5  
(18.8-29.0) 
1.5  
(0.9-2.7) 
Population estimate, 
millions (95% CIb) 
3.9 
(3.0-4.8) 
0.7 
(0.5-1.0) 
1.3 
(0.8-1.9) 
1.6 
(1.1-2.0) 
0.1 
(0.05-0.2) 
 n (column weighted percent [95% CI]) 
Reside in nursing home 33 
(6.3 [4.2-9.4]) 
32 
(65.3 [49.1-78.6)] 
33 
(53.1 [31.3-73.7]) 
44 
(52.7 [34.6-70.1]) 
6 
(39.7 [18.3-65.9]) 
Dementia stagec      
Mild 170 
(84.7 [75.8-90.8]) 
11 
(23.6 [7.9-52.6]) 
29 
(59.0 [40.8-74.9]) 
52 
(49.0 [34.8-63.4]) 
3 
(32.6 [12.3-62.5]) 
Moderate 24 
(6.5 [3.2-12.8)] 
19 
(36.4 [16.8-61.9]) 
23 
(27.6 [14.4-46.3]) 
26 
(24.1 [12.8-40.6]) 
4 
(34.5 [13.5-63.9]) 
Severe 39 
(8.8 [4.8-15.4)] 
26 
(40.0 [24.8-57.3]) 
18 
(13.5 [6.0-27.4]) 
25 
(26.9 [14.2-45.0]) 
6 
(33.0 [12.0-63.9]) 
Cholinesterase Inhibitor 
or memantine 
29 
(14.1 [7.2-26.9]) 
18 
(38.4 [18.3-63.3]) 
12 
(17.8 [7.8-35.7]) 
23 
(34.4 [19.0-54.0]) 
4 
(30.3 [9.6-64.0]) 
Other Psychotropic 
Medication 
     
Antipsychotic n/ad n/a 16 
(20.0 [9.1-38.5]) 
20 
(20.5 [10.1-37.0]) 
7 
(37.0 [17.0-62.7]) 
Sedative-hypnotic n/a 16 
(35.8 [16.1-62.0]) 
n/a 20 
(26.1 [14.4-42.6]) 
6 
(43.1 [12.8-79.6]) 
Antidepressant n/a 20 
(44.2 [22.0-69.0]) 
20 
(31.4 [17.0-50.6]) 
n/a 8 
(47.8 [24.9-71.7]) 
Mood Stabilizer n/a 7 
(5.2 [2.1-12.5]) 
6 
(3.4 [1.0-10.4]) 
8 
(3.1 [1.3-7.4]) 
n/a 
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Any n/a 32 
(65.1 [42.9-82.3]) 
37 
(44.3 [28.1-61.9]) 
43 
(44.7 [29.3-61.3]) 
12 
(82.4 [28.3-98.2]) 
a Medication groups are not mutually exclusive  
b CI: confidence interval 
c As classified by Clinical Dementia Rating Scale (CDR) Score: Mild (CDR 0.5-1.0); Moderate (CDR 2.0); Severe (CDR 
3.0-5.0) 
d n/a: not applicable 
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Table 2. Sample Characteristics of ADAMS Participants with Dementia 
 
(1) 
No medication 
n=234 
(2) 
Antipsychotic 
n=62 
(3) 
Sedative-hypnotic 
n=51 
(4) 
Antidepressant 
n=67 
Between- 
Group 
Differencesa,  
p<0.05 
Age Group          
  70-79 (n, weighted %)b 44 17.3 13 30.8 6 21.5 20 42.2 1<4 
  80-89 125 65.0 30 52.7 27 63.3 33 44.0 none 
  >90 65 17.8 19 16.5 18 15.2 14 13.8 none 
Female 151 66.0 46 72.6 35 71.3 46 69.5 none 
Ethnicity          
  Non-Hispanic White 149 81.3 50 86.3 36 83.8 50 88.1 none 
  Non-Hispanic Black 64 14.6 9 11.5 9 4.9 10 6.6 1>3, 1>4 
  Other 21 4.1 3 2.2 6 11.3 7 5.3 none 
Married 63 34.6 17 26.0 10 12.5 19 23.3 1>3 
Lives in NH 33 6.3 33 61.3 21 47.0 22 34.8 1<2, 1<3, 1<4 
Education          
  <12y 138 45.7 34 48.2 32 42.9 39 50.5 none 
  HS graduate 51 28.5 14 17.6 13 37.5 12 15.9 none 
  >12y 45 25.8 14 34.2 6 19.6 16 33.6 none 
Dementia diagnosis          
  AD 179 70.4 49 75.6 40 75.8 38 51.5 none 
  Vascular 32 17.4  6 8.4 8 20.8 18 26.0 1>2 
  Other 23 12.2  7 16.0 3 3.4 11 22.5 1>3 
Dementia stagec          
  Mild  170 84.7 14 25.9 27 72.3 42 66.5 1>2, 1>4 
  Moderate  24 6.5  21 36.5 13 16.8 14 11.7 1<2 
  Severe  39 8.8 27 37.6 11 10.9 11 21.8 1<2 
Seen a psychiatristd 7 1.5  9 12.0 2 3.6 6 16.5 1<2, 1<4 
Medical history          
  Stroke 84 35.2 24 42.4 15 25.8 30 40.6 none 
  Fall 108 47.5 35 56.4 26 62.3 35 46.2 none 
  Seizure disorder 19 5.4 7 11.1 3 2.0 4 7.9 none 
  Hypertension 148 68.6 35 44.6 31 73.0 46 67.4 1>2 
  Heart disease 40 22.1 12 14.4 8 14.3 21 35.9 none 
  Diabetes 26 11.1 9 12.8 9 8.3 14 17.9 none 
  Chronic respiratory 
problem 
36 13.8 11 31.3 15 52.7 17 21.0 1<3 
  Cancer 67 30.1 16 20.2 20 41.8 16 13.2 1<4 
  Major depressive episode 45 16.1 26 48.9 17 39.6 46 66.1 1<2, 1<4 
  Bipolar disorder 1 0.3 1 1.0 0 0.0 0 0.0 none 
  Schizophrenia 0 0.0 2 11.6 1 1.1 1 3.9 none 
  Alcohol use 138 68.5 30 50.3 26 46.5 31 52.9 none 
  Tobacco use 106 50.5 26 39.7 22 52.8 27 52.0 none 
Total number of 
medications (mean, SEMe) 
5.7 0.3 10.6 1.1 10.2 1.2 10.4 0.8 1<2, 1<3, 1<4 
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MMSEf  (mean, SEM) 19.2 0.7 13.2 1.4 17.4 0.8 17.6 1.1 1>2 
NPI totalg,h  (mean, SEM) 4.5 1.0 12.6 2.1 11.8 3.9 6.9 1.1 1<2, 1<3 
NPI categoryg          
  0 domains 116 58.3 11 22.5 18 30.0 17 21.3 1>2, 1>3, 1>4 
  1-2 domains 69 28.6 25 32.0 17 33.5 25 51.6 1<4 
  >3 domains 42 13.2 24 45.5 15 36.5 21 27.2 1<2, 1<3 
NPI caregiver distressg,i  
(mean, SEM) 
3.1 1.0 4.9 1.5 6.1 2.1 3.7 0.6 1<3 
a Medication groups are mutually exclusive. The right-most column indicates whether a characteristic for a medication group 
differs in a statistically significant fashion (p<0.05) from the no medication group. For example, a smaller proportion of non-
medication users (1) were in the youngest age bracket compared to antidepressant users (4), represented as “1<4”. 
b
 Cells indicate n and weighted percent within each respective medication group (column) unless noted otherwise. 
c As classified by Clinical Dementia Rating Scale (CDR) Score: Mild (CDR 0.5-1.0); Moderate (CDR 2.0); Severe (CDR 3.0-5.0); 
n=413 
d n=354          
e SEM: standard error of the mean        
f n=371; range 0-30          
g n=400          
h range: 0-120          
i range: 0-50          
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Figure 1. Estimated Prevalence of Neuropsychiatric Symptoms by Medication Groupa  
 
a Medication groups are mutually exclusive. 
b Brackets indicate 95% confidence intervals. 
* Antipsychotic > none, sedative-hypnotic > none; p<0.05 
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** Antipsychotic > none; p<0.05 
*** Antidepressant > none; p<0.05 
This article is protected by copyright. All rights reserved.
27 
Table 3. Association of Overall Neuropsychiatric Symptom Prevalence with Psychotropic Usea 
 
 
Antipsychotic (n=286) Sedative-hypnotic (n=276) Antidepressant (n=289) 
 
Adjustedb 
OR  
(95% CI) 
P 
value 
Adjustedc 
OR  
(95% CI) 
P  
value 
Adjustedb 
OR  
(95% CI) 
P 
value 
Adjustedc 
OR  
(95% CI) 
P  
value 
Adjustedb 
OR  
(95% CI) 
P 
value 
Adjustedc 
OR  
(95% CI) 
P  
value 
Neuropsychiatric Inventory 
Domains   
   
  
   
  
  
  
  0 ref ref ref ref ref ref  
  1-2 2.54 
(0.85-7.58) 
0.09 2.28 
(0.66-7.84) 
0.18 2.24 
(0.52-9.56) 
0.19 1.94 
(0.37-10.14) 
0.42 4.62 
(1.60-13.34) 
0.006 3.63 
(1.21-10.89) 
0.02 
  >3 7.40 
(2.46-22.24) 
0.001 3.91 
(1.60-9.56) 
0.004 5.20 
(1.74-15.55) 
0.005 3.84 
(0.93-15.87) 
0.06 5.36 
(2.04-14.05) 
0.001 4.11 
(1.32-12.81) 
0.02 
Resides in nursing home  
  (ref: no) 
  8.96 
(4.19-19.18) 
<0.001   15.59 
(5.08-47.80) 
<0.001   11.23 
(3.57-35.59) 
<0.001 
Dementia Stage             
  Mild   ref    ref    ref  
  Moderate   7.09 
(1.85-27.13) 
0.006   1.27 
(0.29-5.48) 
0.74   2.68 
(0.93-7.77) 
0.07 
  Severe   3.56 
(1.24-10.18) 
0.02   0.42 
(0.08-2.33) 
0.31   1.29 
(0.34-4.90) 
0.70 
a Odds ratio (OR) reflects odds of medication use relative to the no medication group. Medication groups are mutually exclusive. 
b Adjusted for age (linear term), gender, and survey year. 
     c Adjusted for age (linear term), gender, survey year, nursing home residence, and dementia stage. 
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Table 4. Association of Neuropsychiatric Symptom Domain Clusters and Associated Caregiver 
Distress with Psychotropic Usea 
 
Antipsychotic (n=286) Sedative-hypnotic (n=276) Antidepressant (n=289) 
 Domain Cluster 
Adjustedb 
OR (95% CI) P value 
Adjustedb  
OR (95% CI) P value 
Adjustedb  
OR (95% CI) P value 
Delusions +  
Hallucinations +  
Agitationc 
1.12 
(1.00-1.24) 
0.04 X X X X 
  Caregiver distressd 0.99 
(0.80-1.24) 
0.96 X X X X 
Anxiety +  
Agitationc 
X X 1.28 
(1.06-1.55) 
0.01 X X 
  Caregiver distressd X X 0.89 
(0.71-1.12) 
0.31 X X 
Depression +  
Apathyc 
X X X X 0.97 
(0.87-1.08) 
0.52 
  Caregiver distressd X X X X 1.22 
(0.99-1.50) 
0.07 
Resides in nursing 
home (ref: no) 
9.47 
(4.48-20.03) 
<0.001 12.94 
(4.43-37.78) 
<0.001 14.62 
(4.53-47.19) 
<0.001 
Dementia Stage       
  Mild ref  ref  ref  
  Moderate 6.90 
(2.15-22.12) 
0.002 1.32 
(0.37-4.76) 
0.66 2.74 
(0.88-8.51) 
0.08 
  Severe 3.29 
(1.08-10.00) 
0.04 0.39 
(0.09-1.59) 
0.18 1.51 
(0.34-6.65) 
0.57 
a Odds ratio reflects odds of medication use relative to the no medication group. Medication groups are 
mutually exclusive. 
b Adjusted for age (linear term), gender, survey year, nursing home residence, and dementia stage. 
c Domain cluster variable is continuous and derived by adding the NPI scores for each domain listed in 
the cell. Odds ratio reflects the odds of medication associated with 1 additional NPI point from domains 
represented. 
d Caregiver distress variable is continuous and derived by adding the NPI caregiver distress scores for 
the respective participant domains.  
This article is protected by copyright. All rights reserved.
29 
REFERENCES 
American Geriatrics Society 2015 Beers Criteria Update Expert Panel. 2015. American 
Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication 
use in older adults. J Am Geriatr Soc. Epub ahead of print: DOI: 10.1111/jgs.13702. 
Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, Bentham P, Fox C, Holmes C 
& Katona C. 2011. Sertraline or mirtazapine for depression in dementia (hta-sadd): A 
randomised, multicentre, double-blind, placebo-controlled trial. The Lancet 378: 403-
411. 
Beers MH. 1997. Explicit criteria for determining potentially inappropriate medication use by the 
elderly: An update. Arch Intern Med 157: 1531-1536. 
Cummings JL. 1997. The neuropsychiatric inventory assessing psychopathology in dementia 
patients. Neurology 48: 10S-16S. 
Folstein MF, Folstein SE & Mchugh PR. 1975. "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189-198. 
Heeringa SG, Fisher GG, Hurd MD, Langa KM, Ofstedal BM, Plassman BL, Rodgers WL, & 
Weir DR. 2009. Aging, Demographics, and Memory Study (ADAMS). Sample design, 
weighting, and analysis for ADAMS. 
http://hrsonline.isr.umich.edu/sitedocs/userg/ADAMS SampleWeights_Jun2009.pdf 
Accessed October 15, 2014. 
Huybrechts KF, Rothman KJ, Silliman RA, Brookhart MA & Schneeweiss S. 2011. Risk of death 
and hospital admission for major medical events after initiation of psychotropic 
medications in older adults admitted to nursing homes. CMAJ 183: E411-9. 
This article is protected by copyright. All rights reserved.
 30 
Gruber-Baldini AL, Stuart B, Zuckerman IH, Simoni-Wastila L & Miller R. 2007. Treatment of 
dementia in community-dwelling and institutionalized medicare beneficiaries. J Am 
Geriatr Soc 55: 1508-1516. 
Kales HC, Gitlin LN & Lyketsos CG. 2015. Assessment and management of behavioral and 
psychological symptoms of dementia. BMJ 350: h369. 
Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chiang C, Cunningham F, Schneider LS 
& Blow FC. 2012. Risk of mortality among individual antipsychotics in patients with 
dementia. Am J Psychiatry 169: 71-79. 
Kales HC, Zivin K, Kim HM, Valenstein M, Chiang C, Ignacio RV, Ganoczy D, Cunningham F, 
Schneider LS & Blow FC. 2011. Trends in antipsychotic use in dementia 1999-2007. 
Arch Gen Psychiatry 68: 190-197. 
Landes AM, Sperry SD, Strauss ME & Geldmacher DS. 2001. Apathy in alzheimer's disease. J 
Am Geriatr Soc 49: 1700-1707. 
Langa KM, Plassman BL, Wallace RB, Herzog AR, Heeringa SG, Ofstedal MB, Burke JR, 
Fisher GG, Fultz NH, Hurd MD, Potter GG, Rodgers WL, Steffens DC, Weir DR & Willis 
RJ. 2005. The aging, demographics, and memory study: Study design and methods. 
Neuroepidemiology 25: 181-191. 
Lyketsos CG, Carrillo MC, Ryan JM, Khachaturian AS, Trzepacz P, Amatniek J, Cedarbaum J, 
Brashear R & Miller DS. 2011. Neuropsychiatric symptoms in alzheimer’s disease. 
Alzheimer's & Dementia 7: 532-539. 
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J & Dekosky S. 2002. Prevalence of 
neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 288: 
1475-1483. 
This article is protected by copyright. All rights reserved.
 31 
Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC & Breitner JC. 2000. Mental 
and behavioral disturbances in dementia: Findings from the cache county study on 
memory in aging. Am J Psychiatry 157: 708-714. 
Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS & Kales HC. 2015. 
Antipsychotics, other psychotropics, and the risk of death in patients with dementia: 
Number needed to harm. JAMA Psychiatry 72: 438-445. 
Maust DT, Mavandadi S, Eakin A, Streim JE, Difillipo S, Snedden T & Oslin DW. 2011. 
Telephone-based behavioral health assessment for older adults starting a new 
psychiatric medication. Am J Geriatr Psychiatry 19: 851-858. 
McKhann G, Drachman D, Folstein M, Katzman R, Price D & Stadlan EM. 1984. Clinical 
diagnosis of alzheimer's disease report of the nincds‐ adrda work group* under the 
auspices of department of health and human services task force on alzheimer's disease. 
Neurology 34: 939-939. 
Morris JC. 1993. The clinical dementia rating (CDR): Current version and scoring rules. 
Neurology 43: 2412-2414. 
Okura T & Langa KM. 2011. Caregiver burden and neuropsychiatric symptoms in older adults 
with cognitive impairment: The aging, demographics, and memory study (adams). 
Alzheimer Dis Assoc Disord 25: 116-21. 
Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG & Langa KM. 2010. Prevalence of 
neuropsychiatric symptoms and their association with functional limitations in older 
adults in the united states: The aging, demographics, and memory study. J Am Geriatr 
Soc 58: 330-337. 
This article is protected by copyright. All rights reserved.
 32 
Olfson M, Blanco C, Liu SM, Wang S & Correll CU. 2012. National trends in the office-based 
treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 
69: 1247-1256. 
Paulose‐ Ram R, Safran MA, Jonas BS, Gu Q & Orwig D. 2007. Trends in psychotropic 
medication use among us adults. Pharmacoepidemiol Drug Saf 16: 560-570. 
Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, 
Potter GG, Rodgers WL, Steffens DC, Mcardle JJ, Willis RJ & Wallace RB. 2008. 
Prevalence of cognitive impairment without dementia in the United States. Ann Intern 
Med 148: 427-434. 
Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, 
Potter GG, Rodgers WL, Steffens DC, Willis RJ & Wallace RB. 2007. Prevalence of 
dementia in the United States: The Aging, Demographics, and Memory Study. 
Neuroepidemiology 29: 125-132. 
Plassman BL, Langa KM, Mccammon RJ, Fisher GG, Potter GG, Burke JR, Steffens DC, Foster 
NL, Giordani B, Unverzagt FW, Welsh-Bohmer KA, Heeringa SG, Weir DR & Wallace 
RB. 2011. Incidence of dementia and cognitive impairment, not dementia in the United 
States. Ann Neurol 70: 418-426. 
Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, Marano C, 
Meinert CL, Mintzer JE, Munro CA, Pelton G, Rabins PV, Rosenberg PB, Schneider LS, 
Shade DM, Weintraub D, Yesavage J, Lyketsos CG & Cit ADRG. 2014. Effect of 
citalopram on agitation in Alzheimer disease: The citAD randomized clinical trial. JAMA 
311: 682-691. 
This article is protected by copyright. All rights reserved.
 33 
Rhee Y, Csernansky J, Emanuel L, Chang C & Shega J. 2011. Psychotropic medication burden 
and factors associated with antipsychotic use: An analysis of a population‐ based 
sample of community‐ dwelling older persons with dementia. J Am Geriatr Soc 59: 
2100-2107. 
Rockwood K, Howlett SE, Macknight C, Beattie BL, Bergman H, Hébert R, Hogan DB, Wolfson 
C & Mcdowell I. 2004. Prevalence, attributes, and outcomes of fitness and frailty in 
community-dwelling older adults: Report from the canadian study of health and aging. 
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59: 
1310-1317. 
Román GC, Tatemichi TK, Erkinjuntti T, Cummings J, Masdeu J, Garcia JA, Amaducci L, 
Orgogozo J-M, Brun A & Hofman A. 1993. Vascular dementia diagnostic criteria for 
research studies: Report of the NINDS‐ AIREN international workshop*. Neurology 43: 
250-250. 
Rosenberg PB, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, Schneider 
LS, Rabins PV, Munro CA & Meinert CL. 2010. Sertraline for the treatment of depression 
in Alzheimer disease. Am J Geriatr Psychiatry 18: 136-145. 
Schnaider Beeri M, Werner P, Davidson M & Noy S. 2002. The cost of behavioral and 
psychological symptoms of dementia (bpsd) in community dwelling Alzheimer's disease 
patients. Int J Geriatr Psychiatry 17: 403-408. 
Schneider LS, Dagerman KS & Insel P. 2005. Risk of death with atypical antipsychotic drug 
treatment for dementia: Meta-analysis of randomized placebo-controlled trials. JAMA 
294: 1934-1943. 
This article is protected by copyright. All rights reserved.
 34 
Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, 
Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA & Group C-
aDS. 2006. Effectiveness of atypical antipsychotic drugs in patients with alzheimer's 
disease. N Engl J Med 355: 1525-1538. 
Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JW & Weir DR. 2014. Cohort profile: The 
Health and Retirement Study (HRS). Int J Epidemiol 43: 576-585. 
Takayanagi Y, Spira AP, Bienvenu OJ, Hock RS, Carras MC, Eaton WW & Mojtabai R. 2015. 
Antidepressant use and lifetime history of mental disorders in a community sample: 
Results from the Baltimore Epidemiologic Catchment Area Study. J Clin Psychiatry 76: 
40-44. 
Taylor DH, Østbye T, Langa KM, Weir D & Plassman BL. 2009. The accuracy of medicare 
claims as an epidemiological tool: The case of dementia revisited. J Alzheimers Dis 17: 
807-815. 
Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB & Borhani NO. 1993. Recruitment of 
adults 65 years and older as participants in the Cardiovascular Health Study. Ann 
Epidemiol 3: 358-366. 
US Food and Drug Administration. 2005. Information for healthcare professionals: Information 
on conventional antipsychotics. US Department of Health and Human Services. 
http://www.fda.gov/Drugs/DrugSafety/ucm124830.htm. Accessed February 2, 2014. 
US Government Accountability Office. 2015. Antipsychotic Drug Use: HHS has initiatives to 
reduce use among older adults in nursing homes, but should expand efforts to other 
settings. http://www.gao.gov/assets/670/668221.pdf. Accessed April 2, 2015. 
This article is protected by copyright. All rights reserved.
 35 
Wang PS, Bohn RL, Glynn RJ, Mogun H & Avorn J. 2001. Hazardous benzodiazepine regimens 
in the elderly: Effects of half-life, dosage, and duration on risk of hip fracture. Am J 
Psychiatry 158: 892-898. 
Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K & Covinsky KE. 2002. Patient and 
caregiver characteristics and nursing home placement in patients with dementia. JAMA 
287: 2090-7. 
 
 
This article is protected by copyright. All rights reserved.
